Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer

(2010) Yousuke Nakai et al.   PANCREAS

Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer

(2010) Shuji Komori et al.   PANCREAS

Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer

(2009) Hiroaki Ohigashi et al.   ANNALS OF SURGERY

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy

(2009) Chun-Nan Yeh et al.   LANGENBECKS ARCHIVES OF SURGERY

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

(2008) Douglas B. Evans et al.   JOURNAL OF CLINICAL ONCOLOGY